Effect of ulinastatin for hepatoprotection following extracorporeal membrane oxygenation.
- Author:
Binfei LI
1
;
Xiaozu LIAO
;
Zhou CHENG
;
Zhigang ZHANG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Extracorporeal Membrane Oxygenation; adverse effects; methods; Glycoproteins; therapeutic use; Humans; Liver; drug effects; physiopathology; Liver Function Tests; Middle Aged; Young Adult
- From: Journal of Southern Medical University 2012;32(10):1511-1512
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the effect of ulinastatin in hepatoprotection following extracorporeal membrane oxygenation (ECMO).
METHODSForty patients with ECMO were randomized into two groups to receive ulinastatin treatment or not. Venous blood samples were collected to test ALT and AST levels following ECMO treatment for 12, 24 and 48 h.
RESULTSThe two groups showed no significant difference in liver function indices before ECMO treatment. In both groups, the liver function worsened significantly after a 12-h ECMO treatment, but improved gradually after 24 h. The liver function damages were obviously lessened in ulinastatin group compared to those in patients without ulinastatin treatment (P<0.05). ECMO treatment significantly improved the liver function of the patients.
CONCLUSIONECMO can significantly improve the liver function. The liver function damage reaches the peak level after a 12-h ECMO treatment, and ulinastatin can protect the liver function in patients undergoing ECMO.
